Neoadjuvant systemic treatment of HER2 positive breast cancer – case report
MUDr. Katarína Petráková, Ph.D.
Klinika komplexní onkologické péče, LF MU a Masarykův onkologický ústav, Brno
The primary goal of neoadjuvant systemic therapy in patients with early breast cancer is the down-staging of the disease and achieving operability of the primarily inoperable tumor or achieving less radical surgery. Achieving complete pathological remission affects the long-term prognosis of patients, mainly in triple negative breast cancer and non-luminal HER2 (human epidermal receptor 2, positive for breast epidermal growth factor 2). In the case report we present a case of a patient with locally advanced HER2-positive breast cancer who achieved complete remission by intensive neoadjuvant systemic treatment using dual HER2 receptor blockade, which could significantly reduce subsequent surgical treatment.
HER2 positive breast cancer, neoadjuvant systemic treatment, trastuzumab, pertuzumab
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...